AU2020273302B2 — Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
Assigned to Asana Biosciences LLC · Expires 2022-08-11 · 4y expired
What this patent protects
The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effect…
USPTO Abstract
The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more 5 of the compounds of formula (I), wherein X, Y, Z, J, M, and R' to R are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be Ireated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer. NNZR5 R 6 HN Z N\ M /J-R R4 X:=y N o R3 347
Drugs covered by this patent
- Nubeqa (darolutamide) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.